Search Results

You are looking at 81 - 90 of 199 items for :

  • "Metastatic breast cancer" x
Clear All
Full access

pretreated ovarian cancer and the common expression of high levels of folate receptor alpha (FRα) in TNBCs support the rationale to determine the activity of mirvetuximab soravtansine in metastatic breast cancer and, if response is confirmed, evaluating the

Full access

Meena S. Moran

protocol to be written, approved, and instituted for accrual. For example, the authors include one US trial in metastatic breast cancer as deviant because the control arm was 75 mg/m 2 of intravenous docetaxel every 21 days, when the corresponding NCCN

Full access

Dabaja Bouthaina MD 7 2012 10 10 7 7 815 815 819 819 0100815 10.6004/jnccn.2012.0085 Metastatic Breast Cancer, Version 1.2012 Featured Updates to the NCCN Guidelines Carlson Robert W. 1 MD Allred D. Craig 2 MD Anderson Benjamin O

Full access

Jeffrey Crawford, David C. Dale, Nicole M. Kuderer, Eva Culakova, Marek S. Poniewierski, Debra Wolff and Gary H. Lyman

. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients . Cancer 2006 ; 106 : 2258 – 2266 . 3. Hryniuk W Bush H . The importance of dose intensity in chemotherapy of metastatic breast cancer . J Clin Oncol

Full access

of Metastatic Breast Cancer Hematologic Malignancies Developments in the Treatment of Multiple Myeloma Guidelines for NHL: Updates to the Management of DLBCL and New Guidelines for T-Cell Lymphoproliferative Disorders Monitoring Molecular

Full access

, the activity of mirvetuximab soravtansine in advanced, heavily pretreated ovarian cancer and the common expression of high levels of FRα in TNBCs support the rationale to determine the activity of mirvetuximab soravtansine in metastatic breast cancer

Full access

Michael D. Stubblefield, Harold J. Burstein, Allen W. Burton, Christian M. Custodio, Gary E. Deng, Maria Ho, Larry Junck, G. Stephen Morris, Judith A. Paice, Sudhakar Tummala and Jamie H. Von Roenn

unexpected off-therapy worsening . Neurology 2005 ; 64 : 1076 – 1077 . 25 Jones SE Erban J Overmoyer B . Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer . J Clin Oncol 2005 ; 23 : 5542 – 5551

Full access

D. Craig Allred, Robert W. Carlson, Donald A. Berry, Harold J. Burstein, Stephen B. Edge, Lori J. Goldstein, Allen Gown, M. Elizabeth Hammond, James Dirk Iglehart, Susan Moench, Lori J. Pierce, Peter Ravdin, Stuart J. Schnitt and Antonio C. Wolff

receptor (PgR), by LB assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group study . Int J Cancer 2000 ; 89 : 111 – 117 . 15 Rhodes A Jasani B

Full access

Tomas G. Lyons and Mark E. Robson

: patients with a g BRCA mutation and unselected patients with triple-negative breast cancer (TNBC). The following sections will discuss the most relevant data with respect to the evolution of PARPi for the treatment of advanced or metastatic breast cancer

Full access

Tanya E. Keenan and Sara M. Tolaney

that recognize tumor-specific neoantigens. One patient with chemorefractory hormone receptor–positive metastatic breast cancer experienced durable complete remission after adoptive transfer of TILs reactive against 4 tumor-specific mutant proteins, 61